FTC Concludes Acular Patent Investigation
This article was originally published in The Pink Sheet Daily
Executive Summary
The Federal Trade Commission has concluded its investigation into whether Allergan unfairly prevented generic competition for Acular (ketorolac ophthalmic solution .5%)